Skip to main content
Equibles
CRBU logo

CRBU · Caribou Biosciences, Inc.

Track CRBU — free

Use CRBU with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CRBU

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.66 +0.05 (+3.11%) At close · Aug 21
Market Cap
$172.60M
Shares
107.21M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.66 Open$1.64 Day$1.62–1.69 52W close$1.39–2.84 Avg vol 30d1.3M Short int11.6M · 10.9% float · 9.4d Short vol60% Last earningsMay 7, 2026 DataJul 2021–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Oct 4, 2027 Est · unconfirmed · in 58 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −9%
below
Price vs 50-day avg −0%
below
RSI (14) 52
neutral
MACD trend Positive
52-week position 19%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +6%
trailing
6-month return −10%
trailing
YTD return +4%
this year
Relative strength −21%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.86% of float · ▲ +0.4% MoM · 9.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
137 holders — mid 3-yr range
Squeeze score 73
high risk · 0–100
Fundamentals
Strong
Revenue growth +12%
Y/Y
EPS growth +4%
Y/Y
Free cash flow $-112.4M
Balance sheet $12.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −51%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−9% Bearish
Price vs 50-day avg
−0% Neutral
RSI (14)
52 Neutral
MACD trend
Positive Bullish
52-week position
19% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +23 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.86% of float · ▲ +0.4% MoM · 9.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
137 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 19% Range high $3
vs 200-day avg -9% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $142.8M as of December 31, 2025 —
Non-GAAP net loss non-GAAP $126.8M full year 2025 —
Non-GAAP net loss per share non-GAAP $1.36 full year 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRBU
Caribou Biosciences, Inc.
this stock
$172.60M +4.4% +11.7% — 10.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $58.31B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
137
% held
45.4%
Net QoQ
+10.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
58
View
Short & Settlement
Short Interest Rising
Shares short
11.6M
Days to cover
9.4d
Change
+45.2K sh
View
Short Volume
Short vol %
60%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$1.6K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
54.9%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$11.2M
Net income (FY)
$-148.1M
EPS diluted
$-1.59
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
11
View
Proposed Sales
Value
$13.6K
Shares
6.9K
Filed
Feb 25, 2026
View
Exempt Offerings
Offering
$115.0M
Filed
Mar 5, 2021
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
CRBU +5.1% +5.7% -9.8% +13.7% +4.4%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +6.4% +2.1% -21.3% +11.2% -7.9%
Key facts CIK 1619856 CUSIP 142038108 13F (30d) 130 filings 129 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)